酒精使用障碍的药物治疗在商业保险成年人中未得到充分利用,他们患有酒精相关的肝病
Sarah R Lieber1, Alex R Jones2, Yue Jiang3
1Department of Medicine, Division of Digestive and Liver Diseases, University of Texas Southwestern (UTSW) Medical Center, Dallas, Texas.
Gastro hep advances
|October 27, 2025
概括
酒精使用障碍 (AUD) 药物治疗在酒精相关性肝病 (ALD) 患者中使用不足. 这项研究强调了低处方率,特别是在肝硬化或脱补偿症患者中,这表明需要提高意识和利用率.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 成 药物 药物 药物 药物
- 药理学 药理学是指药理学的学科.
背景情况:
- 酒精使用障碍 (AUD) 药物治疗已被证明可以减少酒精相关肝病 (ALD) 患者的不良结果.
- 在一个大型的国家队列中描述AUD药物治疗的现实世界利用对于了解当前治疗差距至关重要.
研究的目的:
- 描述AUD药物治疗在商业保险的美国成年人中大量,全国代表性的使用模式.
- 在患有和没有ALD的患者中确定与接受AUD药物治疗相关的因素.
主要方法:
- 使用PharMetrics Plus for Academics索赔数据库进行了回顾性分析.
- 确定了被诊断为AUD的成年人,并检查了他们接受药物治疗,治疗模式和治疗时间.
- 使用后勤回归来确定与药物治疗接收相关的因素.
主要成果:
- 在28625名AUD患者中,1640人患有ALD,439人患有急性酒精相关肝炎 (AAH).
- 药物治疗被规定给14.5%的没有ALD的患者,2.3%的ALD肝硬化患者,9.8%的AAH患者.
- 与药物治疗接收相关的因素包括精神病诊断和女性性别,而ALD肝硬化和肝衰竭与未接收相关.
结论:
- 在商业保险的美国成年人中,AUD药物治疗的使用显著不足,特别是那些患有ALD和肝脏不补偿症的人.
- 提供者应该意识到处方率较低,特别是对于肝硬化和晚期肝病的男性患者.
- 可能需要进行干预措施,以改善在肝病严重程度范围内的AUD药物治疗的获取和利用.
相关概念视频
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
179
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
179
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
210
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
210
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
248
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
248
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
208
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
208
01:28Drug Therapy
239
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
239
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
165
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
165